ArticleAdvances in radiation oncology2026
Impact of Updated Level IVa Nodal Delineation on Thyroid Dose and Hypothyroidism Risk in Nasopharyngeal Carcinoma.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The 2024 and 2025 international consensus guidelines redefined the anterior border of the level IVa elective nodal volume for nasopharyngeal carcinoma (NPC). This study aimed to provide the first dosimetric validation of this anatomic refinement by quantifying its impact on thyroid and larynx doses and translating these reductions into clinically interpretable normal tissue complication probability (NTCP) estimates. Methods and Materials: Thirty patients with NPC treated with helical tomotherapy were selected to represent a full spectrum of lower cervical nodal involvement. For each patient, 2 comparative treatment plans for different nodal clinical target volume (CTVn) definitions were generated: (1) CTVn based on 2018 guidelines, defining the level IVa anterior border at the anterior edge of the sternocleidomastoid muscle; and (2) CTVn based on 2024/2025 guidelines, shifting this border to the posterior edge of the infrahyoid ribbon muscles. Plans were optimized to minimize thyroid and larynx doses while maintaining equivalent target coverage. Dosimetric parameters and NTCP for hypothyroidism and laryngeal edema were compared using paired analyses. Results: The updated CTVn delineation significantly reduced thyroid mean dose from 48.5 Gy to 44.8 Gy ( Conclusions: Adopting the updated 2024/2025 international consensus guidelines for level IVa delineation significantly reduces radiation dose to the thyroid and larynx without compromising target coverage. This translates into a clinically meaningful reduction in the risk of primary hypothyroidism, supporting the widespread implementation of these guidelines to improve survivorship outcomes in patients with NPC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.